Health Care & Life Sciences » Biotechnology | Silence Therapeutics PLC

Silence Therapeutics PLC

Silence Therapeutics PLC
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
70.07 M
Public Float
-
Silence Therapeutics PLC
Stock Exchange London Stock Exchange
EPS
GBP0.26
Market Cap
GBP54.89 M
Shares Outstanding
70.07 M
Public Float
27.98 M

Profile

Address
72 Hammersmith Road
London Greater London W14 8TH
United Kingdom
Employees -
Website http://silence-therapeutics.com
Updated 07/08/2019
Silence Therapeutics Plc engages in the development of ribonucleic acid (RNA) therapeutics. It develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins.

Financials

View All

Andrew John McGlashan Richards
Non-Executive Chairman
David Horn Solomon
Chief Executive Officer & Director